Sharon Hall

Sharon Hall has served as vice president, regulatory at Allay Therapeutics since April 2021. She brings nearly 30 years of experience in pharmaceuticals and biotech regulatory affairs, during which time she has successfully overseen submission for multiple NDAs, MAAs, INDs, and FDA audits.

Prior to Allay, she was an independent consultant for various pharmaceutical companies and vice president, regulatory affairs at Revance Therapeutics (NASDAQ: RVNC), a biotech focused on innovative aesthetic and therapeutic offerings. Sharon has served in director-level positions at multiple drug delivery and pharmaceutical companies including Pharmacofore and Connetics and Aerogen. She holds bachelor’s degrees in biology and psychology from the University of Texas at San Antonio.